A new humanized in vitro model of IgE-mediated rapid desensitization

Background Rapid drug desensitization (RDD) is widely used to re-introduce medications that have caused an IgEmediated hypersensitivity in allergic patients. However, RDD protocols are largely based on empiric experience and few in vitro models have explored the rationale guiding the rate at which the dose should be increased, what the starting dose should be and how the time elapsed between doses affect the effectiveness of desensitization. This study addresses these issues in a new humanized in vitro model of rapid desensitization.